Bioanalysis
The Year in Review 2025
Biodistribution and Transcript Quantification in Mouse Tissues Using ddPCR
Microsampling with Impact-Assisted Extraction for Hematocrit-Free Assays
Volumetric Microsampling with Hybridization LC–MS/MS for Antisense Oligonucleotide Quantitation
Highlights From the International Society for the Advancement of Cytometry Conference 2025 by Martin Turcotte
CYTO 2025, the 38th annual Congress of the International Society for the Advancement of Cytometry, is the premier, inclusive, and international conference on the many facets of cytometry science and engineering.
Highlights From the 2025 American Society for Mass Spectrometry Conference | By Jean-François Larocque and Benjamin Charron
We were thrilled to represent Altasciences at this year’s American Society for Mass Spectrometry (ASMS) conference in Baltimore. With 6,000 scientists, students, and industry professionals from around the globe in attendance, it was an excellent opportunity to learn about the latest developments in mass spectrometry and share insights with other passionate scientists.
ISSUE NO. 44 — The Importance of Cytokine Release Assays to Derisk the Development of Immunomodulatory Drugs
New immunomodulatory drugs have the potential to cause serious immune-related adverse events, including cytokine release syndrome (CRS). CRS is a systemic inflammatory response characterized by the release of
In Issue 44 of The Altascientist, we review strategies, including those implemented at Altasciences, for developing, qualifying, and implementing cytokine release assays (CRAs) to assess the safety of test articles in vitro to complement in vivo preclinical safety assessments, in addition to:
- the importance of nonclinical cytokine release evaluation
- customized approaches to CRA use in drug development
- top five aspects to consider before running a CRA
- Altasciences’ case results
- how Altasciences can help
Drugs that are likely to require CRAs as part of derisking their development include, but are not limited to:
Case Study: Two Examples of Successful Automation Integration at Altasciences for Pharmacokinetic Studies
By Martin Rougée, Optimization Scientist, Bioanalytical Operations
Automation offers several advantages to any industry. For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. For biotechnology and pharmaceutical companies, automation can decrease their drug-to-market development time and remain financially competitive in an evolving market.
Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development
The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.
The Year in Review 2024
